Clario has chosen Box as its single, integrated solution to consolidate regulated and unregulated content in the cloud, according to Box, Inc., the leading Content Cloud. Clario, a renowned clinical trial data management firm, has already implemented Box to power safe collaboration among its 2,600 employees.
Clario is a prominent provider of decentralized (DCT), hybrid, and site-based clinical trial endpoint technology. Clario has conducted over 19,000 clinical trials and contributed 870 regulatory approvals in the previous 30 years. In the two years between 2019 and 2020, the firm backed 70 percent of all FDA approvals.
“Clario generates rich clinical evidence by fusing scientific expertise and global scale with a groundbreaking endpoint technology platform, minimizing risk in clinical trials around the globe. It is crucial to maintain the highest quality across every aspect of our work, and for that reason we have standardized all regulated and unregulated content using Box as our single validated, secure platform,”
Jay Ferro, Clario’s Chief Technology & Information Officer
The company has evolved via acquiring cutting-edge biotechnology companies since its foundation in 1972. In 2021, two top clinical research data management technology businesses, ERT and Bioclinica, joined to form Clario.
“Clario is leading the way in clinical trial technology that will transform patients’ lives,” said Manu Vohra, Managing Director, Global Life Sciences at Box. “We’re incredibly excited that Box is playing a central role as Clario moves forward, powering GxP use cases across the merged organization and helping consolidate 12 different content management systems into one.”
GxP Validation was first announced by Box in 2018 as a novel solution to ensuring GxP compliance in the cloud. Clario joins a growing list of major life science and biotechnology companies, including AstraZeneca, Amgen, and Allergan, in embracing Box to power new working methods.